Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
113 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape. H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 5, 16 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 4 molecules, respectively. Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Influenza A Virus, H3N2 Subtype Infections - Overview Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development AbbVie Inc AIMM Therapeutics BV Aphios Corp BiondVax Pharmaceuticals Ltd Celltrion Inc FluGen Inc Glide Pharmaceutical Technologies Ltd ILiAD Biotechnologies LLC Inovio Pharmaceuticals Inc Johnson & Johnson Medicago Inc MedImmune LLC Mucosis BV NanoViricides Inc Novavax Inc OPKO Health Inc Protein Sciences Corp Sanofi Pasteur SA Sarepta Therapeutics Inc SK Chemicals Co Ltd Takeda Pharmaceutical Company Ltd VBI Vaccines Inc Visterra Inc Zydus Cadila Healthcare Ltd Influenza A Virus, H3N2 Subtype Infections - Drug Profiles APP-0205 - Drug Profile Product Description Mechanism Of Action R&D Progress APP-309 - Drug Profile Product Description Mechanism Of Action R&D Progress Aspidasept - Drug Profile Product Description Mechanism Of Action R&D Progress AV-5075S - Drug Profile Product Description Mechanism Of Action R&D Progress AV-5080 - Drug Profile Product Description Mechanism Of Action R&D Progress cetylpyridinium chloride - Drug Profile Product Description Mechanism Of Action R&D Progress CR-8020 - Drug Profile Product Description Mechanism Of Action R&D Progress CR-8043 - Drug Profile Product Description Mechanism Of Action R&D Progress CTP-27 - Drug Profile Product Description Mechanism Of Action R&D Progress Fluad (quadrivalent) - Drug Profile Product Description Mechanism Of Action R&D Progress FluGEM - Drug Profile Product Description Mechanism Of Action R&D Progress Gamma-Flu - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H3N2] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H3N2] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H3N2] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H3N2v] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strain A/H3N2v] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-3872 - Drug Profile Product Description Mechanism Of Action R&D Progress M-001 - Drug Profile Product Description Mechanism Of Action R&D Progress NBP-607 - Drug Profile Product Description Mechanism Of Action R&D Progress NEO-8877 - Drug Profile Product Description Mechanism Of Action R&D Progress NVINF-1 - Drug Profile Product Description Mechanism Of Action R&D Progress NVINF-2 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides for Influenza Infections - Drug Profile Product Description Mechanism Of Action R&D Progress pertussis [strain BPZE1] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress PNSIA-28 - Drug Profile Product Description Mechanism Of Action R&D Progress radavirsen - Drug Profile Product Description Mechanism Of Action R&D Progress REDEE FLU - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for RSV and Influenza A Infections - Drug Profile Product Description Mechanism Of Action R&D Progress VIS-410 - Drug Profile Product Description Mechanism Of Action R&D Progress Influenza A Virus, H3N2 Subtype Infections - Dormant Projects Influenza A Virus, H3N2 Subtype Infections - Discontinued Products Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones Featured News & Press Releases Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't Yet Exist Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics BV, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Protein Sciences Corp, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra Inc, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2017 Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
